La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Merck Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Merck ha un patrimonio netto totale di $43.6B e un debito totale di $37.8B, che porta il suo rapporto debito/patrimonio netto a 86.6%. Le sue attività totali e le sue passività totali sono rispettivamente $112.6B e $69.0B. L'EBIT di Merck è $19.8B rendendo il suo rapporto di copertura degli interessi 20.7. Ha liquidità e investimenti a breve termine pari a $11.4B.

Informazioni chiave

86.6%

Rapporto debito/patrimonio netto

US$37.79b

Debito

Indice di copertura degli interessi	20.7x
Contanti	US$11.35b
Patrimonio netto	US$43.65b
Totale passività	US$68.98b
Totale attività	US$112.63b

Aggiornamenti recenti sulla salute finanziaria

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Jul 18

Recent updates

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 01

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Jul 31

Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE

Jul 24

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Jul 18

Merck: Positive Developments, But Watch The Q2 Earnings

Jul 12

Merck: Among The Best Health Care GARP Plays Today

Jul 03

What Merck & Co., Inc.'s (NYSE:MRK) P/S Is Not Telling You

Jun 30

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $38.2B ) di MRK superano le sue passività a breve termine ( $26.1B ).

Passività a lungo termine: Le attività a breve termine di MRK ( $38.2B ) non coprono le sue passività a lungo termine ( $42.9B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 60.6% ) di MRK è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di MRK si è ridotto da 95.9% a 86.6% negli ultimi 5 anni.

Copertura del debito: Il debito di MRK è ben coperto dal flusso di cassa operativo ( 44.2% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di MRK sono ben coperti dall'EBIT ( 20.7 x copertura).

Merck Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Recent updates

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Merck Appears Ready To Return To June Highs (Technical Analysis)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck's Change To Profit Guidance Provides An Opportunity

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck: Buy This Bargain Before It's Gone

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Insufficient new directors

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) PPlus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

First quarter dividend of US$0.77 announced

Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Eyebiotech Limited.

Merck: Positive Developments, But Watch The Q2 Earnings

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000E Value Index

Merck: Among The Best Health Care GARP Plays Today

What Merck & Co., Inc.'s (NYSE:MRK) P/S Is Not Telling You

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane